Elan, Andrx Antitrust Battle Over Naproxen Deal Heads Back To District Court
The U.S. Court of Appeals for the 11th Circuit agreed with a Florida district court that the Noerr-Pennington doctrine immunized Elan from an antitrust suit based on generic maker Andrx’s allegations that Elan filed a sham lawsuit to protect its monopoly on the market for a controlled release naproxen medication.
However, the court...
Already a subscriber? Click here to login